849776-66-5

Upstream product

• 936564-96-4 3-(3-trifluoromethyl-benzoylamino)-pyrazine-2-carboxylic acid amide 
• 849776-63-2 C₁₄H₁₀F₃N₃O₃ 
• 36526-32-6 ethyl 3-amino[2,3-b]pyrazine-2-carboxylate 
• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 
• 936564-92-0 3-[bis-(3-trifluoromethyl-benzoyl)-amino]-pyrazine-2-carboxylic acid ethyl ester 

Downstream Products

• 849776-69-8 C₁₃H₆ClF₃N₄ 

Relevant academic research and scientific papers

Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-

QUINAZOLINE DERIVATIVES AS MEDICAMENTS

Quinazoline derivatives have the formula (I) or the pharmaceutically acceptable salts thereof; wherein each of Z5, Z6, Z7 and Z8 is N or CH and wherein one or two Z5, Z6, Z7 and Z8 are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0-3; wherein R1 is independently OH, SH, NH2, OR, SR, NHR, halo or R-halide; wherein two adjacent R1 groups may be joined to form an aliphatic hetero cycle ring of 5-6 members; wherein R2 is independently R, halo, R-halide, OR-halide, NH2, CONH2 or CONHR; wherein R is optionally substituted C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl, or aryl C1-C12 alkyl, containing 0-4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are =O, =N, or OH; and wherein R3 is H or CH3. Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGFβ activity.